KPV: three amino acids off the end of alpha-MSH, and what that fragment does
The shortest peptide in this reference, and an unusual one: the evidence for it points at an intracellular mechanism rather than a receptor, which is why the oral route is taken seriously here in a way it usually should not be.
Regulatory status. Research compound — Orphan Drug Designation in progress for IBD. Not FDA approved. That is the app’s own field, reproduced here rather than summarised. It means no regulator has reviewed a manufacturer’s evidence for identity, purity, potency or safety in people for this compound, so nothing below is a marketing claim about a product you can buy.
Purity, identity and concentration are therefore unverified by anyone but whoever made the vial. The storage rule in the fact box below is general practice for this formulation rather than a specification for a particular product: General handling practice for this formulation. Your supplier’s own insert or COA overrides anything here.
This page names no vendor, no clinic and no testing service, and there is no discount code anywhere on this site — the moment a page like this recommends where to buy, it stops being information.
- Also known as
- Lys-Pro-Val, Alpha-MSH C-terminal tripeptide, α-MSH(11-13)
- Class
- Anti-inflammatory peptide
- Regulatory status
- Research compound — Orphan Drug Designation in progress for IBD. Not FDA approved.
- Before mixing
- Sealed powder tolerates room temperature in transit, but keep it refrigerated at 2–8 °C (36–46 °F) for anything beyond a few weeks, or frozen for months. Keep it dark — the carton it shipped in is doing a job.
- After mixing
- Once reconstituted with bacteriostatic water: refrigerate at 2–8 °C and use within about 28 days. The benzyl alcohol in bacteriostatic water is what buys that window — plain sterile water has no preservative, so a vial mixed with it should be treated as one sitting only. Kits are usually ten vials: only the one you mixed is on that 28-day clock — the sealed ones keep their own, much longer shelf life, so store them as powder, not as solution.
- What ruins it
- Do not freeze a reconstituted vial. Repeated freeze–thaw is one of the more reliable ways to degrade a peptide.
- Handling caveat
- General handling practice for this formulation. Your supplier’s own insert or COA overrides anything here.
A fragment that skips the receptor
Animal-only or theoretical Alpha-melanocyte stimulating hormone has anti-inflammatory properties separate from its pigmentation role, and KPV — lysine, proline, valine — is the last three residues of it. What makes it interesting is that the anti-inflammatory activity appears to survive in the fragment while the melanocortin receptor activity does not: KPV does not meaningfully stimulate MC1R, so it does not produce the tanning or the other melanocortin effects that the full agonists do.
The mechanism proposed is intracellular. Rather than binding a surface receptor, the tripeptide is reported to be taken up by peptide transporters — PepT1 in intestinal epithelium among them — and to interfere with NF-kB signalling directly inside the cell, which is the master switch for a large part of the inflammatory response. If that account is right it explains both the potency at very low concentrations and the plausibility of an oral route for gut-directed use, since PepT1 is exactly the transporter the gut uses for di- and tripeptides.
The app records no half-life or time to peak, because none has been published. That is why the fact box above carries no pharmacokinetic rows, and it means any duration figure quoted for this compound elsewhere is not coming from a characterisation study.
The gut evidence, and the ceiling on it
Animal-only or theoretical The strongest work is in animal models of colitis, where oral or nanoparticle-delivered KPV reduced inflammation and mucosal damage at strikingly low doses. There is cell-culture work supporting the NF-kB mechanism, and work on skin inflammation from the same direction. It is a coherent and reasonably deep preclinical literature.
What does not exist is a published randomised controlled trial in people, for any indication. The app’s regulatory string notes an orphan drug designation in progress for inflammatory bowel disease, and it is worth being precise about what that means: an orphan designation is a regulatory incentive granted early in development, not a finding about whether something works. It says a sponsor is pursuing an indication. It does not say the compound has been shown to treat it.
So the honest summary is a well-supported preclinical mechanism, an unusually plausible case for an oral route, and no human efficacy data. The gap between the first two and the third is where all the uncertainty sits.
Practical points, and the caution that matters
The app records both oral and subcutaneous rows with different targets — gut-local for the oral, systemic for the injection — and that split follows the mechanism rather than being arbitrary. It also means the two routes are not interchangeable: an oral dose taken for a tendon is relying on systemic absorption of an intact tripeptide, which is a much larger claim than local action on intestinal epithelium.
There is no monitoring marker. The app records inflammatory markers where the underlying condition warrants following them, and nothing on a panel tracks the compound. Assessment is symptomatic over weeks.
The caution that deserves stating: inflammatory bowel disease is a diagnosis with effective treatments, real complications when undertreated, and a course that can look like improvement while damage continues. Substituting an unstudied peptide for treatment that works is the specific harm available here. Anyone using this alongside a diagnosed condition should be doing it with the knowledge of the clinician managing that condition, not instead of them.
The dosing rows the app records
Off-label or community practice Reproduced from the app’s reference so you can see what it holds, not as a recommendation. Which row applies to a particular person, if any, is a clinical decision this page does not make — and rows describing supraphysiological or post-cycle use are filtered out before this table is built, so what you see here is a subset.
| Label | Amount | Route and frequency | Duration recorded |
|---|---|---|---|
| Gut and IBD | 500mcg-1mg orally | Twice daily fasted | 4-8 weeks |
| Systemic anti-inflammatory | 250-500mcg | SubQ once daily | 4-6 weeks |
| Gut Protocol (Oral) | 500mcg–2mg | Oral capsule, twice daily fasted | 4–12 weeks |
| Systemic | 500mcg–1mg | SubQ injection daily | 4–8 weeks |
What the app monitors alongside it
The panel below is the app’s own monitoring note for KPV, verbatim. None of the analytes it names has a page here yet.
- Monitoring panel
- Inflammatory markers (CRP, ESR) if available. Symptom tracking for GI conditions. No specific blood monitoring required.
Drawbacks and risks the app records
From the app’s own entry. The dosing item is the practical one — optimal dosing is not established, so every number in the rows above is convention rather than a finding.
- Limited human clinical trial data
- Not FDA approved
- Oral bioavailability variable
- Quality sourcing critical
- Long-term effects not established
- May need higher oral doses vs SubQ
- Limited human clinical data
- Optimal dosing not yet established
- Multiple administration routes can be confusing
- Short half-life
Questions people actually ask
Does it cause tanning like the other melanocortin peptides?
No. The fragment retains the anti-inflammatory activity and not the receptor activity that drives pigmentation, which is the main reason it is interesting as a separate compound rather than as a version of alpha-MSH.
Does oral KPV actually work?
For gut-local effects the argument is genuinely plausible — PepT1 transports tripeptides and the target tissue is the intestine itself. For systemic effects from an oral dose it is a much weaker claim. Neither has a human trial behind it.
What does "orphan drug designation in progress" mean?
That a sponsor is pursuing a rare-disease indication and seeking the regulatory incentives that come with it. It is a statement about development intent, not about evidence, and it is routinely quoted as though it were an endorsement.
Can it replace IBD treatment?
No, and that is the one thing on this page worth being blunt about. Inflammatory bowel disease has treatments that work and complications when it is undertreated. This belongs beside a clinician’s plan, not instead of one.
Where the load-bearing numbers come from
Named rather than linked. Publisher URLs move, and a citation that resolves to a 404 two years from now is worse than one you can search for by name — every entry below is findable from the title and year alone.
- KPV as the C-terminal tripeptide of alpha-MSH
- Established peptide chemistry of the melanocortin family
- NF-kB interference and PepT1 uptake
- Cell-culture and animal colitis models published from the 2000s onward
- Orphan drug designation
- The regulatory string in the fact box is app.html’s own field; a designation is a development incentive, not an efficacy finding
- Absence of pharmacokinetic data
- app.html holds no half-life or time-to-peak entry for this compound, which is why no such rows appear above
A compound judged on symptoms over weeks needs the weeks recorded. TherapyLog keeps the dose, the route and your own notes on one timeline.
Save this dose to your log